Published in J Immunother on May 01, 2011
Trial watch: Dendritic cell-based interventions for cancer therapy. Oncoimmunology (2012) 1.51
The future of high-grade glioma: Where we are and where are we going. Surg Neurol Int (2015) 1.50
An update on vaccine therapy and other immunotherapeutic approaches for glioblastoma. Expert Rev Vaccines (2013) 1.08
Immunotherapy advances for glioblastoma. Neuro Oncol (2014) 1.07
Impact of temozolomide on immune response during malignant glioma chemotherapy. Clin Dev Immunol (2012) 1.05
Recent developments on immunotherapy for brain cancer. Expert Opin Emerg Drugs (2012) 1.03
A dendritic cell vaccine pulsed with autologous hypochlorous acid-oxidized ovarian cancer lysate primes effective broad antitumor immunity: from bench to bedside. Clin Cancer Res (2013) 1.01
Modulation of radiochemoimmunotherapy-induced B16 melanoma cell death by the pan-caspase inhibitor zVAD-fmk induces anti-tumor immunity in a HMGB1-, nucleotide- and T-cell-dependent manner. Cell Death Dis (2015) 0.99
Toward precision medicine in glioblastoma: the promise and the challenges. Neuro Oncol (2015) 0.98
Current vaccine trials in glioblastoma: a review. J Immunol Res (2014) 0.96
Immunotherapy for the treatment of glioblastoma. Cancer J (2012) 0.93
α-type-1 polarized dendritic cell-based vaccination in recurrent high-grade glioma: a phase I clinical trial. BMC Cancer (2012) 0.91
Silencing of the TGF-β1 gene increases the immunogenicity of cells from human ovarian carcinoma. J Immunother (2012) 0.90
Immune-checkpoint blockade and active immunotherapy for glioma. Cancers (Basel) (2013) 0.88
Immunotherapy for cancer in the central nervous system: Current and future directions. Oncoimmunology (2015) 0.88
Interleukin-13 receptor alpha 2-targeted glioblastoma immunotherapy. Biomed Res Int (2014) 0.86
Fractionated radiotherapy is the main stimulus for the induction of cell death and of Hsp70 release of p53 mutated glioblastoma cell lines. Radiat Oncol (2014) 0.86
A new hope in immunotherapy for malignant gliomas: adoptive T cell transfer therapy. J Immunol Res (2014) 0.85
Vaccination strategies for neuro-oncology. Neuro Oncol (2015) 0.85
Recent advances in the field of anti-cancer immunotherapy. BBA Clin (2015) 0.85
Personalized medicine for gliomas. Surg Neurol Int (2015) 0.85
Irradiation of necrotic cancer cells, employed for pulsing dendritic cells (DCs), potentiates DC vaccine-induced antitumor immunity against high-grade glioma. Oncoimmunology (2015) 0.85
Significance of interleukin-13 receptor alpha 2-targeted glioblastoma therapy. Neuro Oncol (2014) 0.84
Cellular-based immunotherapies for patients with glioblastoma multiforme. Clin Dev Immunol (2012) 0.84
Cross-presentation of viral antigens in dribbles leads to efficient activation of virus-specific human memory T cells. J Transl Med (2014) 0.83
Cytokine responsiveness of CD8(+) T cells is a reproducible biomarker for the clinical efficacy of dendritic cell vaccination in glioblastoma patients. J Immunother Cancer (2014) 0.83
Effective Treatment of Established GL261 Murine Gliomas through Picornavirus Vaccination-Enhanced Tumor Antigen-Specific CD8+ T Cell Responses. PLoS One (2015) 0.83
The development of dendritic cell vaccine-based immunotherapies for glioblastoma. Semin Immunopathol (2017) 0.82
Improving vaccine efficacy against malignant glioma. Oncoimmunology (2016) 0.81
Natural killer cells in intracranial neoplasms: presence and therapeutic efficacy against brain tumours. J Neurooncol (2013) 0.81
New routes for allergen immunotherapy. Hum Vaccin Immunother (2012) 0.81
Immunomonitoring in glioma immunotherapy: current status and future perspectives. J Neurooncol (2015) 0.79
Brain Tumor Immunotherapy: What have We Learned so Far? Front Oncol (2015) 0.79
Cell-based immunotherapy against gliomas: from bench to bedside. Mol Ther (2013) 0.78
Exploiting the Immunogenic Potential of Cancer Cells for Improved Dendritic Cell Vaccines. Front Immunol (2016) 0.78
Ubiquitinated proteins enriched from tumor cells by a ubiquitin binding protein Vx3(A7) as a potent cancer vaccine. J Exp Clin Cancer Res (2015) 0.76
Viral-mimicking protein nanoparticle vaccine for eliciting anti-tumor responses. Biomaterials (2016) 0.76
DCVax®-L--developed by Northwest Biotherapeutics. Hum Vaccin Immunother (2014) 0.76
Intralymphatic immunotherapy and vaccination in mice. J Vis Exp (2014) 0.75
The Safety of available immunotherapy for the treatment of glioblastoma. Expert Opin Drug Saf (2016) 0.75
Advances in Immunotherapy for Glioblastoma Multiforme. J Immunol Res (2017) 0.75
Immunotherapy for neuro-oncology: the critical rationale for combinatorial therapy. Neuro Oncol (2015) 0.75
Identification of hub genes and regulatory factors of glioblastoma multiforme subgroups by RNA-seq data analysis. Int J Mol Med (2016) 0.75
Radiotherapy and immunotherapy: a beneficial liaison? Nat Rev Clin Oncol (2017) 0.75
Immunotherapy in glioblastoma: emerging options in precision medicine. CNS Oncol (2016) 0.75
Dendritic cell vaccination for glioblastoma multiforme: review with focus on predictive factors for treatment response. Immunotargets Ther (2014) 0.75
Letter to the editor. J Immunother Cancer (2014) 0.75
Analysis of long non-coding RNA expression profiles identifies novel lncRNA biomarkers in the tumorigenesis and malignant progression of gliomas. Oncotarget (2017) 0.75
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med (2005) 74.55
Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol (1990) 18.71
Selective CD4+ lymphopenia in melanoma patients treated with temozolomide: a toxicity with therapeutic implications. J Clin Oncol (2004) 4.06
Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment. Clin Cancer Res (2005) 3.35
Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI). Cancer Immunol Immunother (2007) 3.16
Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma. Cancer Res (2006) 3.02
Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma. Cancer Res (2004) 2.89
Guidelines for the development and incorporation of biomarker studies in early clinical trials of novel agents. Clin Cancer Res (2010) 2.44
Expansion of FOXP3high regulatory T cells by human dendritic cells (DCs) in vitro and after injection of cytokine-matured DCs in myeloma patients. Blood (2006) 2.36
Incidence and prognostic impact of FoxP3+ regulatory T cells in human gliomas. Clin Cancer Res (2008) 2.15
Prostaglandin E2 and tumor necrosis factor alpha cooperate to activate human dendritic cells: synergistic activation of interleukin 12 production. J Exp Med (1997) 2.14
Vaccination elicits correlated immune and clinical responses in glioblastoma multiforme patients. Cancer Res (2008) 2.12
Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration. Cancer Res (2001) 2.11
Postoperative adjuvant dendritic cell-based immunotherapy in patients with relapsed glioblastoma multiforme. Clin Cancer Res (2008) 2.04
Toward the harmonization of immune monitoring in clinical trials: quo vadis? Cancer Immunol Immunother (2007) 2.00
Clinical and immunologic effects of intranodal autologous tumor lysate-dendritic cell vaccine with Aldesleukin (Interleukin 2) and IFN-{alpha}2a therapy in metastatic renal cell carcinoma patients. Clin Cancer Res (2009) 1.94
An increase in CD4+CD25+FOXP3+ regulatory T cells in tumor-infiltrating lymphocytes of human glioblastoma multiforme. Neuro Oncol (2006) 1.92
Clinical evaluation of dendritic cell vaccination for patients with recurrent glioma: results of a clinical phase I/II trial. Clin Cancer Res (2005) 1.76
Primary brain tumors treated with steroids and radiotherapy: low CD4 counts and risk of infection. Int J Radiat Oncol Biol Phys (2005) 1.69
Vaccination of recurrent glioma patients with tumour lysate-pulsed dendritic cells elicits immune responses: results of a clinical phase I/II trial. Br J Cancer (2003) 1.63
Clinical responsiveness of glioblastoma multiforme to chemotherapy after vaccination. Clin Cancer Res (2004) 1.57
Real-time quantitative polymerase chain reaction assessment of immune reactivity in melanoma patients after tumor peptide vaccination. J Natl Cancer Inst (2000) 1.53
The failure of current immunotherapy for malignant glioma. Tumor-derived TGF-beta, T-cell apoptosis, and the immune privilege of the brain. Brain Res Brain Res Rev (1995) 1.51
Initiation of immune responses in brain is promoted by local dendritic cells. J Immunol (2004) 1.48
A flow cytometric method to estimate the precursor frequencies of cells proliferating in response to specific antigens. J Immunol Methods (1999) 1.46
Surgery and adjuvant dendritic cell-based tumour vaccination for patients with relapsed malignant glioma, a feasibility study. Br J Cancer (2004) 1.39
Immunological responses in a patient with glioblastoma multiforme treated with sequential courses of temozolomide and immunotherapy: case study. Neuro Oncol (2007) 1.38
Intranodal administration of peptide-pulsed mature dendritic cell vaccines results in superior CD8+ T-cell function in melanoma patients. J Clin Oncol (2003) 1.34
T cells traffic from brain to cervical lymph nodes via the cribroid plate and the nasal mucosa. J Leukoc Biol (2006) 1.30
Results of a phase I dendritic cell vaccine trial for malignant astrocytoma: potential interaction with adjuvant chemotherapy. J Clin Neurosci (2008) 1.21
Integration of autologous dendritic cell-based immunotherapy in the primary treatment for patients with newly diagnosed glioblastoma multiforme: a pilot study. J Neurooncol (2010) 1.18
Delayed-type hypersensitivity response is a predictor of peripheral blood T-cell immunity after HER-2/neu peptide immunization. Clin Cancer Res (2000) 1.13
How to drain without lymphatics? Dendritic cells migrate from the cerebrospinal fluid to the B-cell follicles of cervical lymph nodes. Blood (2005) 1.12
Intranodal immunization with tumor lysate-pulsed dendritic cells enhances protective antitumor immunity. Cancer Res (2001) 1.10
Thymic CD8+ T cell production strongly influences tumor antigen recognition and age-dependent glioma mortality. J Immunol (2003) 1.10
Use of cell-tracking dyes to determine proliferation precursor frequencies of antigen-specific T cells. Methods Mol Biol (2004) 1.05
Developing a rational tumor vaccine therapy for renal cell carcinoma: immune yin and yang. Clin Cancer Res (2007) 0.93
Multiparameter precursor analysis of T-cell responses to antigen. J Immunol Methods (2003) 0.87
The olfactory route for cerebrospinal fluid drainage into the peripheral lymphatic system. Neuropathol Appl Neurobiol (2006) 0.87
Effects of concomitant temozolomide and radiation therapies on WT1-specific T-cells in malignant glioma. Jpn J Clin Oncol (2010) 0.84
Dye dilution proliferation assay: application of the DDPA to identify tumor-specific T cell precursor frequencies in clinical trials. Immunol Invest (2007) 0.79
Surgical vs nonoperative treatment for lumbar disk herniation: the Spine Patient Outcomes Research Trial (SPORT): a randomized trial. JAMA (2006) 12.22
Surgical versus nonsurgical therapy for lumbar spinal stenosis. N Engl J Med (2008) 10.35
Effects of a palliative care intervention on clinical outcomes in patients with advanced cancer: the Project ENABLE II randomized controlled trial. JAMA (2009) 7.99
Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med (2015) 7.51
Surgical vs nonoperative treatment for lumbar disk herniation: the Spine Patient Outcomes Research Trial (SPORT) observational cohort. JAMA (2006) 7.45
Surgical versus nonsurgical treatment for lumbar degenerative spondylolisthesis. N Engl J Med (2007) 6.72
Stem cell engraftment at the endosteal niche is specified by the calcium-sensing receptor. Nature (2005) 5.54
Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol (2012) 5.32
Digital breast tomosynthesis: initial experience in 98 women with abnormal digital screening mammography. AJR Am J Roentgenol (2007) 4.88
Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol (2005) 4.64
Design of the Spine Patient outcomes Research Trial (SPORT). Spine (Phila Pa 1976) (2002) 4.42
Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes. Cancer Res (2009) 4.16
Surgical treatment of spinal stenosis with and without degenerative spondylolisthesis: cost-effectiveness after 2 years. Ann Intern Med (2008) 3.65
Surgical versus nonoperative treatment for lumbar disc herniation: four-year results for the Spine Patient Outcomes Research Trial (SPORT). Spine (Phila Pa 1976) (2008) 3.46
Gradient directed regularization for sparse Gaussian concentration graphs, with applications to inference of genetic networks. Biostatistics (2005) 3.45
Ex vivo analysis of human memory CD4 T cells specific for hepatitis C virus using MHC class II tetramers. J Clin Invest (2003) 3.40
Electromagnetic breast imaging: results of a pilot study in women with abnormal mammograms. Radiology (2007) 3.29
The increasing incidence of thyroid cancer: the influence of access to care. Thyroid (2013) 3.00
Surgical compared with nonoperative treatment for lumbar degenerative spondylolisthesis. four-year results in the Spine Patient Outcomes Research Trial (SPORT) randomized and observational cohorts. J Bone Joint Surg Am (2009) 2.99
Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the Writing Committee of the American Society for Apheresis: the sixth special issue. J Clin Apher (2013) 2.97
Quantitative fluorescence in intracranial tumor: implications for ALA-induced PpIX as an intraoperative biomarker. J Neurosurg (2011) 2.86
Surgical versus nonoperative treatment for lumbar spinal stenosis four-year results of the Spine Patient Outcomes Research Trial. Spine (Phila Pa 1976) (2010) 2.80
Three phase II cytokine working group trials of gp100 (210M) peptide plus high-dose interleukin-2 in patients with HLA-A2-positive advanced melanoma. J Clin Oncol (2008) 2.77
Imaging breast adipose and fibroglandular tissue molecular signatures by using hybrid MRI-guided near-infrared spectral tomography. Proc Natl Acad Sci U S A (2006) 2.56
Phase I and pharmacokinetic study of YM155, a small-molecule inhibitor of survivin. J Clin Oncol (2008) 2.35
Interpreting hemoglobin and water concentration, oxygen saturation, and scattering measured in vivo by near-infrared breast tomography. Proc Natl Acad Sci U S A (2003) 2.34
Sun exposure and melanoma risk at different latitudes: a pooled analysis of 5700 cases and 7216 controls. Int J Epidemiol (2009) 2.32
Descriptive epidemiology and prior healthcare utilization of patients in the Spine Patient Outcomes Research Trial's (SPORT) three observational cohorts: disc herniation, spinal stenosis, and degenerative spondylolisthesis. Spine (Phila Pa 1976) (2006) 2.30
A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma. Clin Cancer Res (2004) 2.28
Randomized trial of an allogeneic melanoma lysate vaccine with low-dose interferon Alfa-2b compared with high-dose interferon Alfa-2b for Resected stage III cutaneous melanoma. J Clin Oncol (2007) 2.19
Characterization of hemoglobin, water, and NIR scattering in breast tissue: analysis of intersubject variability and menstrual cycle changes. J Biomed Opt (2004) 2.17
Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin. J Clin Oncol (2013) 2.11
Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America. Cancer (2010) 2.10
Spine patient outcomes research trial: do outcomes vary across centers for surgery for lumbar disc herniation? Neurosurgery (2012) 2.10
Concordance of multiple analytical approaches demonstrates a complex relationship between DNA repair gene SNPs, smoking and bladder cancer susceptibility. Carcinogenesis (2005) 2.08
Incidence of transitional cell carcinoma of the bladder and arsenic exposure in New Hampshire. Cancer Causes Control (2004) 2.07
Lumbar spine: reliability of MR imaging findings. Radiology (2008) 2.06
Long-term outcomes of lumbar spinal stenosis: eight-year results of the Spine Patient Outcomes Research Trial (SPORT). Spine (Phila Pa 1976) (2015) 1.96
Clinical and immunologic effects of intranodal autologous tumor lysate-dendritic cell vaccine with Aldesleukin (Interleukin 2) and IFN-{alpha}2a therapy in metastatic renal cell carcinoma patients. Clin Cancer Res (2009) 1.94
Ventriculoperitoneal shunt in patients with leptomeningeal metastasis. Neurology (2005) 1.91
Partial Cox regression analysis for high-dimensional microarray gene expression data. Bioinformatics (2004) 1.90
Electromagnetic breast imaging: average tissue property values in women with negative clinical findings. Radiology (2004) 1.85
A pediatric, practice-based, randomized trial of drinking and smoking prevention and bicycle helmet, gun, and seatbelt safety promotion. Pediatrics (2002) 1.83
Effects of food on the relative bioavailability of lapatinib in cancer patients. J Clin Oncol (2009) 1.79
Effect of head impacts on diffusivity measures in a cohort of collegiate contact sport athletes. Neurology (2013) 1.79
The project ENABLE II randomized controlled trial to improve palliative care for rural patients with advanced cancer: baseline findings, methodological challenges, and solutions. Palliat Support Care (2009) 1.76
Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301. J Clin Oncol (2009) 1.75
The cost effectiveness of surgical versus nonoperative treatment for lumbar disc herniation over two years: evidence from the Spine Patient Outcomes Research Trial (SPORT). Spine (Phila Pa 1976) (2008) 1.72
Degenerative spondylolisthesis: does fusion method influence outcome? Four-year results of the spine patient outcomes research trial. Spine (Phila Pa 1976) (2009) 1.71
The impact of epidural steroid injections on the outcomes of patients treated for lumbar disc herniation: a subgroup analysis of the SPORT trial. J Bone Joint Surg Am (2012) 1.70
A palindrome-mediated mechanism distinguishes translocations involving LCR-B of chromosome 22q11.2. Hum Mol Genet (2003) 1.67
A prospective clinical study of proximal humerus fractures treated with a locking proximal humerus plate. J Orthop Trauma (2011) 1.66
Feasibility study of a randomized controlled trial of a telephone-delivered problem-solving-occupational therapy intervention to reduce participation restrictions in rural breast cancer survivors undergoing chemotherapy. Psychooncology (2010) 1.65
Consideration of postpartum management in HIV-positive Haitian women: an analysis of CD4 decline, mortality, and follow-up after delivery. J Acquir Immune Defic Syndr (2012) 1.62
Focal lesion in the splenium of the corpus callosum on FLAIR MR images: a common finding with aging and after brain radiation therapy. AJNR Am J Neuroradiol (2003) 1.61
A computationally efficient hypothesis testing method for epistasis analysis using multifactor dimensionality reduction. Genet Epidemiol (2009) 1.61
Differential memory test sensitivity for diagnosing amnestic mild cognitive impairment and predicting conversion to Alzheimer's disease. Neuropsychol Dev Cogn B Aging Neuropsychol Cogn (2009) 1.61
A fatal central nervous system enterovirus 68 infection. Arch Pathol Lab Med (2011) 1.61
Pegylated interferon alfa-2b treatment for patients with solid tumors: a phase I/II study. J Clin Oncol (2002) 1.60
Statistical analysis of nonlinearly reconstructed near-infrared tomographic images: Part I--Theory and simulations. IEEE Trans Med Imaging (2002) 1.59
Symbolic modeling of epistasis. Hum Hered (2007) 1.58
Increased brain activation during working memory in cognitively intact adults with the APOE epsilon4 allele. Am J Psychiatry (2006) 1.55
Interferon alfa-2a for melanoma metastases. Lancet (2002) 1.55
Verbal fluency performance in amnestic MCI and older adults with cognitive complaints. Arch Clin Neuropsychol (2008) 1.51
Assessment of cancer risk and environmental levels of arsenic in New Hampshire. Int J Hyg Environ Health (2002) 1.51
A pooled analysis of melanocytic nevus phenotype and the risk of cutaneous melanoma at different latitudes. Int J Cancer (2009) 1.51
In vivo hemoglobin and water concentrations, oxygen saturation, and scattering estimates from near-infrared breast tomography using spectral reconstruction. Acad Radiol (2006) 1.50
Chronic exposure to arsenic in the drinking water alters the expression of immune response genes in mouse lung. Environ Health Perspect (2009) 1.48
A phase II study of bevacizumab and high-dose interleukin-2 in patients with metastatic renal cell carcinoma: a Cytokine Working Group (CWG) study. J Immunother (2013) 1.48
The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma. Nat Rev Clin Oncol (2013) 1.46
The effects of a high-fat meal on single-dose vemurafenib pharmacokinetics. J Clin Pharmacol (2014) 1.45
Cholinergic enhancement of frontal lobe activity in mild cognitive impairment. Brain (2004) 1.44
Long-term follow-up of a phase II trial of chemotherapy plus hormone therapy for biochemical relapse after definitive local therapy for prostate cancer. Urology (2013) 1.44
Bladder cancer SNP panel predicts susceptibility and survival. Hum Genet (2009) 1.43
Enhanced efficacy and reduced toxicity of multifactorial adjuvants compared with unitary adjuvants as cancer vaccines. Blood (2008) 1.43
Pigmentary characteristics and moles in relation to melanoma risk. Int J Cancer (2005) 1.40
Regionally specific atrophy of the corpus callosum in AD, MCI and cognitive complaints. Neurobiol Aging (2005) 1.39
Surgical versus nonoperative treatment for lumbar disc herniation: eight-year results for the spine patient outcomes research trial. Spine (Phila Pa 1976) (2014) 1.39
When should a rheumatologist suspect a mitochondrial myopathy? Arthritis Care Res (Hoboken) (2011) 1.39
Overnight, room temperature hold of whole blood followed by 42-day storage of red blood cells in additive solution-7. Transfusion (2014) 1.39
RNA interference inhibition of matrix metalloproteinase-1 prevents melanoma metastasis by reducing tumor collagenase activity and angiogenesis. Cancer Res (2007) 1.39
Mitochondrial dysfunction in patients with hypotonia, epilepsy, autism, and developmental delay: HEADD syndrome. J Child Neurol (2002) 1.39
Comparison of manual and automated determination of hippocampal volumes in MCI and early AD. Brain Imaging Behav (2010) 1.36
Comparative effectiveness evidence from the spine patient outcomes research trial: surgical versus nonoperative care for spinal stenosis, degenerative spondylolisthesis, and intervertebral disc herniation. Spine (Phila Pa 1976) (2011) 1.36
The association of lifestyle and dietary factors with the risk for serrated polyps of the colorectum. Cancer Epidemiol Biomarkers Prev (2009) 1.35
Laboratory diet profoundly alters gene expression and confounds genomic analysis in mouse liver and lung. Chem Biol Interact (2008) 1.34
Reliability of readings of magnetic resonance imaging features of lumbar spinal stenosis. Spine (Phila Pa 1976) (2008) 1.34
Tracking antigen-driven responses by flow cytometry: monitoring proliferation by dye dilution. Cytometry A (2008) 1.33
Automated region detection based on the contrast-to-noise ratio in near-infrared tomography. Appl Opt (2004) 1.32
Dosimetry based on EPR spectral analysis of fingernail clippings. Health Phys (2010) 1.31
American society for apheresis guidelines support use of red cell exchange transfusion for severe malaria with high parasitemia. Clin Infect Dis (2013) 1.29
Phase I study of the safety, tolerability, and pharmacokinetics of oral CP-868,596, a highly specific platelet-derived growth factor receptor tyrosine kinase inhibitor in patients with advanced cancers. J Clin Oncol (2009) 1.28
GeneComps and ChemComps: a new CTD metric to identify genes and chemicals with shared toxicogenomic profiles. Bioinformation (2009) 1.27